Management of Deranged Prothrombin Time/International Normalized Ratio (PT/INR)

Assessment and Clinical Significance

The management of deranged PT/INR should be tailored to the underlying cause, clinical context, and severity of the abnormality, with treatment only indicated for symptomatic patients or those with INR >2.0 who are not on anticoagulation therapy 1
PT/INR is primarily designed and validated to assess coagulation status and bleeding risk in patients receiving vitamin K antagonist (VKA) therapy, not as a general screen for coagulopathy 1
Normal PT/INR indicates normal functioning of the extrinsic and common coagulation pathways, including adequate levels of factors II, V, VII, X, and fibrinogen 2
Deranged PT/INR may result from vitamin K antagonist therapy (e.g., warfarin) 1
Deranged PT/INR may result from liver dysfunction 1, 2
Deranged PT/INR may result from disseminated intravascular coagulation 2
Deranged PT/INR may result from congenital factor deficiencies 2

The target INR range for most indications is 2.0-3.0, as recommended by the European Society of Cardiology 3, 4
Higher INR targets (2.5-3.5) may be required for specific mechanical heart valve patients, according to the European Heart Journal 5
The risk of major bleeding increases when INR exceeds 4.5 and rises steeply above INR of 6.0, as reported in the European Heart Journal 5
For patients on VKA therapy with INR within the therapeutic range (2.0-3.0 for most indications), the current dosing regimen should be continued, as recommended by the European Heart Journal 3, 4
For patients on VKA therapy with INR above the therapeutic range but <4.5 (without bleeding), the next dose should be reduced or held, as suggested by the European Heart Journal 5
For patients on VKA therapy with INR 4.5-6.0 (without bleeding), 1-2 doses of anticoagulant should be held, as recommended by the European Heart Journal 5
For patients on VKA therapy with INR >6.0 (without bleeding), anticoagulant should be held, as suggested by the European Heart Journal 5
For patients on VKA therapy with any INR and clinically significant bleeding, anticoagulant should be held, as recommended by the European Heart Journal 4, 5

For asymptomatic patients with mild INR elevations (1.0-2.0), there is no evidence that plasma transfusion provides clinical benefit, as reported in the Journal of Thrombosis and Haemostasis 1
For patients not on anticoagulation with mildly elevated INR (1.0-2.0) without bleeding, observation only is recommended, as suggested by the Journal of Thrombosis and Haemostasis 1
For patients not on anticoagulation with moderately elevated INR (2.0-4.0) without bleeding, the underlying cause should be identified and treated, as recommended by the Journal of Thrombosis and Haemostasis 1, 2
For patients not on anticoagulation with severely elevated INR (>4.0) or any elevated INR with bleeding, the underlying cause should be identified and treated, as suggested by the Journal of Thrombosis and Haemostasis 1 and the European Heart Journal 5

For trauma patients, early and repeated monitoring of hemostasis using PT/INR is recommended, with a PTr >1.2 indicating traumatic coagulopathy and PTr >1.5 indicating severe coagulopathy, as reported in Critical Care 6
For patients requiring lumbar puncture or other invasive procedures, anticoagulant medication should be reviewed before the procedure, as recommended by Alzheimer's and Dementia 7
The HAS-BLED score can help assess bleeding risk in patients with atrial fibrillation, with a score ≥3 indicating high risk, as reported in the European Heart Journal 3, 4